ACP
KRYS icon

Acuta Capital Partners’s Krystal Biotech KRYS Stock Holding History

Acuta Capital Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,573
Closed -$1.87M – 34
2025
Q3 		$1.87M Buy
+10,573
New +$1.58M 1.93% 15
2021
Q4 		– Sell
-72,551
Closed -$3.79M – 46
2021
Q3 		$3.79M Buy
+72,551
New +$4.29M 1.34% 24

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acuta Capital Partners's KRYS Position: Q4 2025 in Review

Acuta Capital Partners sold out of Krystal Biotech (KRYS) in Q4 2025, closing a stake of 10,573 shares — an estimated $1.87M sold.

Acuta Capital Partners first reported a position in KRYS in Q3 2021 and held it in 2 quarters. The position peaked at $3.79M in Q3 2021. 334 funds tracked by Wall St. Rank hold KRYS as of Q4 2025.

  • Acuta Capital Partners reported no remaining Krystal Biotech position as of Q4 2025 after selling out during the quarter.
  • Acuta Capital Partners sold 10,573 Krystal Biotech shares in Q4 2025, an estimated $1.87M.
  • Acuta Capital Partners first reported a position in Krystal Biotech in Q3 2021 and held it in 2 quarters.
  • Acuta Capital Partners's Krystal Biotech position peaked at $3.79M in Q3 2021.
  • 334 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2025.

Based on Acuta Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.